Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Beluga Health vs Cora Health

Beluga Health
Graded #430

Lower grade

vs+16.700000000000003
Cora Health
Graded #76

Higher grade

The verdict

Cora Health takes it — 72.5/100 to 55.8/100.

Cora Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Cora Health is a direct-to-consumer telehealth platform offering compounded semaglutide ($99–$175/mo) and tirzepatide ($135–$225/mo) with flat per-tier pricing — no surcharge as your dose escalates.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCora Health +29
45
74
Dose & formulationCora Health +32
40
72
Clinical oversightCora Health +6
76
82
Labs & monitoringBeluga Health +8
62
54
FulfillmentCora Health +25
64
89
Contract termsEven
55
55
Beluga Health · left barCora Health · right bar

The numbers

MetricBeluga HealthCora Health
WeighScore55.8/10072.5/100
GradeCC
Scorecard rank#430#76
SemaglutideNot disclosed$175/mo
TirzepatideNot disclosed$225/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Beluga Health

Graded #430 · C

Strengths

  • Supports GLP-1 care with compounded semaglutide and tirzepatide
  • Board-certified providers and a 50-state medical infrastructure
  • LegitScript certified with SOC 2 and ISO 27001 security
  • Pharmacies follow FDA/USP standards with third-party batch testing
  • Powers many DTC brands as a turnkey telehealth backbone

Where it loses points

  • White-label B2B group, not a direct consumer-facing service
  • Offers compounded, not FDA-approved branded, GLP-1s
  • No public consumer pricing for the GLP-1 offering
  • Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
  • Care quality varies by the consumer brand using the platform
Cora Health

Graded #76 · C

Strengths

  • Two named 503A compounding pharmacy partners disclosed on first-party pages (Hallandale Pharmacy + VialsRx)
  • Hallandale Pharmacy is PCAB-accredited and operating since 2003 (independently verified)
  • LegitScript Certified (seal ID 49690100 in footer)
  • Flat per-tier pricing — no dose-escalation surcharge
  • Annual commitment delivers $99/mo semaglutide and $135/mo tirzepatide

Where it loses points

  • Compounded medications are not FDA-approved and not therapeutically equivalent to Wegovy/Zepbound
  • Leanio Health LLC has zero independent operating-history footprint (no BBB, no press, likely <12 months old)
  • Lowest advertised prices require 12-month commitment with no partial refunds
  • No brand-name Wegovy/Zepbound or oral GLP-1 (orforglipron/Rybelsus) options
  • Founder names and funding undisclosed on site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard